Recognising the clinical tension between the potential benefit of abemaciclib if cANC demonstrates additional axillary node macrometastases versus the potential morbidity as a direct result of cANC we examined the outcomes of a historic cohort of women with ER+ HER2− breast cancer who had at least one macrometastatic sentinel node. This evidence concerns the gene ERBB2 and breast carcinoma.